Can a patient experience withdrawal symptoms from Tetrahydrocannabinol (THC)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Cannabis Withdrawal Syndrome: A Real Clinical Entity

Yes, patients can absolutely experience withdrawal symptoms from THC, and this is a well-established, clinically significant syndrome that occurs in approximately 47% of regular cannabis users after cessation. 1

Clinical Recognition and Diagnosis

Cannabis withdrawal syndrome (CWS) is formally recognized in the DSM-5 as a criterion for cannabis use disorders. 2 The diagnosis requires:

  • Abrupt cessation of prolonged or heavy cannabis use 2
  • Three or more of the following symptoms: irritability or anger, anxiety, insomnia, decreased appetite, restlessness, altered mood, and physical symptoms causing significant discomfort (abdominal pain, tremors, sweating, fever, chills, or headache) 2

The most common features include anxiety, irritability, anger or aggression, disturbed sleep/dreaming, depressed mood, and loss of appetite. 3 Less common physical symptoms include chills, headaches, physical tension, sweating, and stomach pain. 3

Timeline and Natural History

Symptom onset typically occurs within 24-48 hours of cessation, with most symptoms peaking between days 2-6. 1, 3, 4 The acute withdrawal phase generally lasts 1-2 weeks, though some symptoms can persist for up to 3 weeks or more in heavy users. 2, 3

  • Onset: 24-72 hours after cessation 2
  • Peak intensity: Days 2-6 3, 4
  • Duration: Most symptoms resolve within 4-14 days 4
  • Cannabis craving: Peaks in the first week but may persist for months or even years 2

This timeline corresponds with the neurobiological recovery of CB1 receptors, which begin to reverse desensitization within 48 hours of abstinence and return to normal functioning within approximately 4 weeks. 2, 5

Risk Factors and Severity Predictors

Patients at highest risk for CWS are those consuming:

  • >1.5 g/day of inhaled cannabis 2
  • >20 mg/day of THC-dominant cannabis oil 2
  • >300 mg/day of CBD-dominant oil 2
  • Cannabis products with unknown THC/CBD content more than 2-3 times per day 2

Women report stronger withdrawal symptoms than men, including more prominent physical symptoms such as nausea and stomach pain. 5 Severity also depends on the amount of cannabis used pre-cessation, heritable factors, and environmental factors. 5

Clinical Significance and Complications

The clinical importance of cannabis withdrawal lies in its role as a precipitant for relapse to cannabis use. 3 This is particularly relevant in perioperative settings where patients may be forced to abruptly discontinue use. 2

A critical pitfall: Pain itself may be a withdrawal symptom and not simply an exacerbation of original chronic pain. 2 Descending pain facilitatory tracts originating in the rostral ventral medulla show increased firing during early abstinence, which can amplify preexisting pain or create new pain. 2

Management Approach

First-Line Treatment

Supportive counseling and psychoeducation are the first-line approaches, despite limited empirical evidence. 3 There are currently no FDA-approved medications specifically for cannabis withdrawal. 3

Symptomatic Management

For specific symptoms:

  • Diarrhea and GI distress: Standard antidiarrheal agents such as loperamide 1
  • Nausea: Ondansetron may be tried, though efficacy is often limited 1
  • Insomnia: Mirtazapine can be beneficial 5
  • Anxiety: Benzodiazepines are a reasonable first-line approach 6

Critical caveat: Avoid opioids entirely, as they worsen nausea, carry addiction risk, and do not address the underlying pathophysiology. 1

Pharmacological Substitution

For patients with significant CWS symptoms in the postoperative period who were consuming high amounts of cannabis, nabilone or nabiximols substitution is appropriate. 2, 7 This is particularly relevant for patients who were consuming:

  • More than 1.5 g/day of high-THC (>20%) smoked cannabis 2
  • More than 20 mg/day of THC oil 2

Patients with suspected CWS should be referred to psychiatry or addiction medicine specialists who can initiate or guide treatment with nabilone or nabiximols and explore other treatment options. 2, 7

Nabilone is a synthetic THC analogue with anxiolytic, anti-emetic, and analgesic properties, but carries risks of drowsiness, dizziness, vertigo, postural hypotension, and dry mouth. 2 Elderly patients are particularly vulnerable to these adverse effects. 7

Inpatient Considerations

Inpatient admission for medically assisted withdrawal may be clinically indicated for patients with:

  • Significant comorbid mental health disorders 3
  • Polysubstance use 3
  • Severe cannabis use disorder 5
  • Low social functioning 5

Monitoring Requirements

Assess for concurrent mental health disorders, particularly anxiety and depression, which are common comorbidities in CWS. 1 Anxiety and depressive symptoms may emerge or intensify during withdrawal. 2

Important Distinction: CWS vs. Cannabinoid Hyperemesis Syndrome

Cannabis withdrawal syndrome must be differentiated from cannabinoid hyperemesis syndrome (CHS), as they present oppositely but can both cause vomiting. 1 In CWS, vomiting occurs after stopping cannabis use, whereas in CHS, vomiting occurs during active chronic use with pathognomonic hot water bathing behavior present in 44-71% of cases. 1

Long-Term Considerations

Provide cannabis cessation counseling and consider psychological support, given that anxiety is a prominent feature of CWS. 1 Some patients may experience protracted withdrawal symptoms—dysphoria, irritability, insomnia, anhedonia, or a vague sense of being unwell—months after opioid elimination, though these symptoms cannot be easily differentiated from underlying chronic conditions. 2

References

Guideline

Management of Cannabis Withdrawal Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical management of cannabis withdrawal.

Addiction (Abingdon, England), 2022

Research

The time course and significance of cannabis withdrawal.

Journal of abnormal psychology, 2003

Research

The cannabis withdrawal syndrome: current insights.

Substance abuse and rehabilitation, 2017

Research

The synthetic cannabinoid withdrawal syndrome.

Journal of addiction medicine, 2013

Guideline

Nabilone Use in Clinical Scenarios

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.